The ups and downs continue as we remain in what could be the developing range. I could be wrong but I think a range bound market would be the most frustrating and money losing market for the largest number of people and hence is the likely outcome. Money might just rotate between sectors moving them […]
The past two weeks or so has seen some large moves on a daily basis and yet there has basically been very little movement in the sector (or market writ large). There seems to be a continued bull versus bear debate ongoing in the market and the basic outlines (if you have seen these articles) […]
What kills bulls runs in the sector? News can but the floodgate of secondaries opening is also a sure why these end. Yesterday saw the opening of the secondary window and while the first wave of secondaries does not always kill bull runs, it seems like we are at the beginning of the end. We […]
I figured the sector was hoping for a merger Monday to really continue the push from Friday. Instead we got a Moderna Monday that is pushing not just the sector but the market. There is really not much more news that I can tell but the ultimately it looks like the old resistance level on […]
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.